News

  1. La Jolla Pharmaceutical Company Announces Completion Of Phase 1 Portion Of GCS-100 Clinical Trial In Chronic Kidney Disease 5/6/2013

    La Jolla Pharmaceutical Company (OTCBB: LJPC) ("La Jolla" and "Company"), a leader in the development of therapeutics targeting galectin proteins, announced today that it has treated the last patient in the Phase 1 (Part A) portion of the Phase 1/2 clinical trial of GCS-100 in patients with chronic kidney disease ("CKD").

  2. Aptalis Selects Transperfect's Trial Interactive Technology As Its Pharmacovigilance System Master File (Psmf) Solution 4/22/2013

    TransPerfect, a leading provider of solutions for global development and commercialization of products to the life sciences industry, announced that Aptalis Pharma ("Aptalis") has implemented Trial Interactive as its global pharmacovigilance system master file (PSMF) solution.

  3. Cellceutix To Commence Clinical Trials For Its Novel Anti-Cancer Drug Kevetrin 9/24/2012

    Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs for hard to treat diseases, is pleased to update shareholders on the status of clinical trials for the Company's novel anti-cancer drug, Kevetrin™, at Harvard Cancer Center's Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center.

  4. Dalton Pharma Services Supports Client Milestone In Dengue Treatment Clinical Trial 7/24/2012

    A clinical trial to treat dengue fever with a new antiviral medicine, Celgosivir, has been initiated in Singapore. The trial follows successful mouse model studies by researchers at the Duke-National University of Singapore (NUS) Graduate Medical School, who established its efficacy (1). Celgosivir, also known as butyl-castanospermine, is derived from the seeds of the Moreton Bay Chestnut tree.

  5. Cellceutix Approved By FDA To Proceed With Clinical Trials On Novel Cancer Drug 6/22/2012

    Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, is pleased to announce that the U.S. Food and Drug Administration ("FDA") has completed the review of the Company's Investigational New Drug (IND) application for Kevetrin™, the Cellcetix's novel anti-cancer compound, and has yesterday informed Cellceutix that "we have completed the review of your submission, and have concluded that you may proceed with the proposed study."

  6. PRA Experts To Present At DIA Annual Conference 6/20/2012

    PRA, a leading Clinical Research Organization, announces that two of our experts will speak at the DIA 48th Annual Meeting being held in Philadelphia from 24-28 June.

  7. Inc Research Selects Transperfect's Trial Interactive Technology As Its Electronic Trial Master File (eTMF) Solution 5/14/2012

    TransPerfect, a leading provider of e-clinical technologies to the life sciences industry, recently announced that INC Research, a therapeutically focused clinical research organization (CRO), has selected Trial Interactive as its global electronic Trial Master File (eTMF) solution.

  8. Oxygen Biotherapeutics To Begin Clinical Study To Determine Efficacy Of Dermacyte® In Relieving Histamine Induced Pruritus 1/10/2012
    Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) announced today that enrollment for the company's first dermatological study will begin later this month at St. John's Medical College Hospital in Bangalore, India.
  9. Del Mar Pharmaceuticals Initiates Glioblastoma Clinical Trial 10/27/2011
    DelMar Pharmaceuticals today announced the initiation of the Company's planned clinical trial with its lead drug candidate, VAL-083, for the treatment of refractory glioblastoma multiforme (GBM).
  10. Approval Of US Pilot Clinical Trial To Evaluate AclarusDx™, The Exonhit Investigational Test For Alzheimer's Disease Diagnosis 10/27/2011
    Exonhit (Paris:ALEHT) announced today the Institutional Review Board (IRB) approval of Exonhit sponsored pilot clinical trial aimed at evaluating the performance of AclarusDx™, a blood based investigational diagnostic test, in US-based patients suffering from memory impairment and newly referred to a reference Memory Center for Alzheimer’s Disease (AD) diagnostic workup. This study will be conducted by the Cleveland Clinic Lou Ruvo Center for Brain Health.